Literature DB >> 9811326

Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.

C F Lippa1, H Fujiwara, D M Mann, B Giasson, M Baba, M L Schmidt, L E Nee, B O'Connell, D A Pollen, P St George-Hyslop, B Ghetti, D Nochlin, T D Bird, N J Cairns, V M Lee, T Iwatsubo, J Q Trojanowski.   

Abstract

Missense mutations in the alpha-synuclein gene cause familial Parkinson's disease (PD), and alpha-synuclein is a major component of Lewy bodies (LBs) in sporadic PD, dementia with LBs (DLB), and the LB variant of Alzheimer's disease (AD). To determine whether alpha-synuclein is a component of LBs in familial AD (FAD) patients with known mutations in presenilin (n = 65) or amyloid precursor protein (n = 9) genes, studies were conducted with antibodies to alpha-, beta-, and gamma-synuclein. LBs were detected with alpha- but not beta- or gamma-synuclein antibodies in 22% of FAD brains, and alpha-synuclein-positive LBs were most numerous in amygdala where some LBs co-localized with tau-positive neurofibrillary tangles. As 12 (63%) of 19 FAD amygdala samples contained alpha-synuclein-positive LBs, these inclusions may be more common in FAD brains than previously reported. Furthermore, alpha-synuclein antibodies decorated LB filaments by immunoelectron microscopy, and Western blots revealed that the solubility of alpha-synuclein was reduced compared with control brains. The presence of alpha-synuclein-positive LBs was not associated with any specific FAD mutation. These studies suggest that insoluble alpha-synuclein aggregates into filaments that form LBs in many FAD patients, and we speculate that these inclusions may compromise the function and/or viability of affected neurons in the FAD brain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811326      PMCID: PMC1853391          DOI: 10.1016/s0002-9440(10)65722-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections.

Authors:  S R Shi; M E Key; K L Kalra
Journal:  J Histochem Cytochem       Date:  1991-06       Impact factor: 2.479

2.  Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease.

Authors:  G Lennox; J Lowe; K Morrell; M Landon; R J Mayer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

3.  Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.

Authors:  M C Irizarry; W Growdon; T Gomez-Isla; K Newell; J M George; D F Clayton; B T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  1998-04       Impact factor: 3.685

4.  [Alzheimer's presenile dementia transmitted in an extended kindred].

Authors:  J F Foncin; D Salmon; V Supino-Viterbo; R G Feldman; G Macchi; P Mariotti; C Scoppetta; G Caruso; A C Bruni
Journal:  Rev Neurol (Paris)       Date:  1985       Impact factor: 2.607

5.  Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly.

Authors:  R H Perry; D Irving; G Blessed; A Fairbairn; E K Perry
Journal:  J Neurol Sci       Date:  1990-02       Impact factor: 3.181

6.  The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity.

Authors:  L Hansen; D Salmon; D Galasko; E Masliah; R Katzman; R DeTeresa; L Thal; M M Pay; R Hofstetter; M Klauber
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

7.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD.

Authors:  D W Dickson; D Ruan; H Crystal; M H Mark; P Davies; Y Kress; S H Yen
Journal:  Neurology       Date:  1991-09       Impact factor: 9.910

9.  Hippocampal lesions in dominantly inherited Alzheimer's disease.

Authors:  R G Struble; R J Polinsky; J C Hedreen; L E Nee; P Frommelt; R G Feldman; D L Price
Journal:  J Neuropathol Exp Neurol       Date:  1991-01       Impact factor: 3.685

10.  Familial Alzheimer's disease in two kindreds of the same geographic and ethnic origin. A clinical and genetic study.

Authors:  J Goudsmit; B J White; L R Weitkamp; B J Keats; C H Morrow; D C Gajdusek
Journal:  J Neurol Sci       Date:  1981-01       Impact factor: 3.181

View more
  129 in total

Review 1.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 2.  Lewy bodies and dementia.

Authors:  D Galasko
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

3.  Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology.

Authors:  J E Galvin; B Giasson; H I Hurtig; V M Lee; J Q Trojanowski
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

4.  Synphilin-1-binding protein NUB1 is colocalized with nonfibrillar, proteinase K-resistant α-synuclein in presynapses in Lewy body disease.

Authors:  Kunikazu Tanji; Fumiaki Mori; Katsumi Kito; Akiyoshi Kakita; Junsei Mimura; Ken Itoh; Hitoshi Takahashi; Tetsu Kamitani; Koichi Wakabayashi
Journal:  J Neuropathol Exp Neurol       Date:  2011-10       Impact factor: 3.685

5.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.

Authors:  J E Galvin; K Uryu; V M Lee; J Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

6.  Tau Interacts with the C-Terminal Region of α-Synuclein, Promoting Formation of Toxic Aggregates with Distinct Molecular Conformations.

Authors:  Anvesh K R Dasari; Rakez Kayed; Sungsool Wi; Kwang Hun Lim
Journal:  Biochemistry       Date:  2019-06-07       Impact factor: 3.162

Review 7.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 8.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

9.  Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome.

Authors:  Carol F Lippa; Andrea L Rosso; Lauren D Stutzbach; Manuela Neumann; Virginia M-Y Lee; John Q Trojanowski
Journal:  Arch Neurol       Date:  2009-12

10.  TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson's disease and dementia with Lewy bodies.

Authors:  Kunikazu Tanji; Tetsu Kamitani; Fumiaki Mori; Akiyoshi Kakita; Hitoshi Takahashi; Koichi Wakabayashi
Journal:  Neurobiol Dis       Date:  2010-01-18       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.